000142330 001__ 142330
000142330 005__ 20240229105147.0
000142330 0247_ $$2doi$$a10.1056/NEJMoa1805762
000142330 0247_ $$2pmid$$apmid:30403938
000142330 0247_ $$2ISSN$$a0028-4793
000142330 0247_ $$2ISSN$$a1533-4406
000142330 0247_ $$2altmetric$$aaltmetric:50960460
000142330 037__ $$aDKFZ-2019-00106
000142330 041__ $$aeng
000142330 082__ $$a610
000142330 1001_ $$aDimopoulos, Meletios A$$b0
000142330 245__ $$aElotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
000142330 260__ $$aWaltham, Mass.$$bMMS$$c2018
000142330 3367_ $$2DRIVER$$aarticle
000142330 3367_ $$2DataCite$$aOutput Types/Journal article
000142330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1549619555_21030
000142330 3367_ $$2BibTeX$$aARTICLE
000142330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142330 3367_ $$00$$2EndNote$$aJournal Article
000142330 520__ $$aThe immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival.A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25; 95% CI, 1.49 to 7.11). The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). A total of 65% of the patients in each group had infections. Infusion reactions occurred in 3 patients (5%) in the elotuzumab group.Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).
000142330 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142330 588__ $$aDataset connected to CrossRef, PubMed,
000142330 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000142330 650_7 $$2NLM Chemicals$$aImmunologic Factors
000142330 650_7 $$01351PE5UGS$$2NLM Chemicals$$aelotuzumab
000142330 650_7 $$04Z8R6ORS6L$$2NLM Chemicals$$aThalidomide
000142330 650_7 $$07S5I7G3JQL$$2NLM Chemicals$$aDexamethasone
000142330 650_7 $$0D2UX06XLB5$$2NLM Chemicals$$apomalidomide
000142330 7001_ $$aDytfeld, Dominik$$b1
000142330 7001_ $$aGrosicki, Sebastian$$b2
000142330 7001_ $$aMoreau, Philippe$$b3
000142330 7001_ $$aTakezako, Naoki$$b4
000142330 7001_ $$aHori, Mitsuo$$b5
000142330 7001_ $$aLeleu, Xavier$$b6
000142330 7001_ $$aLeBlanc, Richard$$b7
000142330 7001_ $$aSuzuki, Kenshi$$b8
000142330 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b9$$udkfz
000142330 7001_ $$aRichardson, Paul G$$b10
000142330 7001_ $$aPopa McKiver, Mihaela$$b11
000142330 7001_ $$aJou, Ying-Ming$$b12
000142330 7001_ $$aShelat, Suresh G$$b13
000142330 7001_ $$aRobbins, Michael$$b14
000142330 7001_ $$aRafferty, Brian$$b15
000142330 7001_ $$aSan-Miguel, Jesús$$b16
000142330 773__ $$0PERI:(DE-600)1468837-2$$a10.1056/NEJMoa1805762$$gVol. 379, no. 19, p. 1811 - 1822$$n19$$p1811 - 1822$$tThe New England journal of medicine$$v379$$x1533-4406$$y2018
000142330 909CO $$ooai:inrepo02.dkfz.de:142330$$pVDB
000142330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000142330 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142330 9141_ $$y2018
000142330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142330 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142330 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEW ENGL J MED : 2017
000142330 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142330 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142330 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142330 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142330 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142330 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142330 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142330 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bNEW ENGL J MED : 2017
000142330 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x0
000142330 980__ $$ajournal
000142330 980__ $$aVDB
000142330 980__ $$aI:(DE-He78)G170-20160331
000142330 980__ $$aUNRESTRICTED